Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nicotinate
Drug ID BADD_D01563
Description Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565]
Indications and Usage Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections.[L7550,L7553,L7556,L7559] Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia.[L7562,L7565] It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia.[L7562,L7565] Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia.[L7562,L7565] Finally niacin is indicated to treat severe hypertriglyceridemia.[L7562,L7565]
Marketing Status approved; investigational; nutraceutical
ATC Code C04AC01; C10AD02
DrugBank ID DB00627
KEGG ID D00049
MeSH ID D009525
PubChem ID 937
TTD Drug ID Not Available
NDC Product Code 72919-420; 59651-018; 59651-019; 62135-497; 71741-047; 47335-613; 50268-584; 62135-498; 65162-321; 65162-323; 68180-222; 68180-223; 62331-016; 68180-221; 71741-020; 47335-539; 47335-614; 71740-001; 71740-201; 62704-0027; 65162-322; 51552-0559; 62175-322; 33342-189; 59651-020; 62175-320; 25441-0095; 65372-1194; 33342-187; 51407-267; 51407-268
UNII 2679MF687A
Synonyms Niacin | Nicotinic Acid | 3-Pyridinecarboxylic Acid | 3 Pyridinecarboxylic Acid | Niacin Lithium Salt, Hemihydrate | Niacin Potassium Salt | Potassium Salt, Niacin | Niacin Sodium Salt | Sodium Salt, Niacin | Niacin Tartrate | Tartrate, Niacin | Niacin Copper (2+) Salt | Niacin Hydrochloride | Hydrochloride, Niacin | Niacin Iron (2+) Salt | Niacin Tosylate | Tosylate, Niacin | Niacin Zinc Salt | Nicamin | Nico-400 | Nico 400 | Nico400 | Nicobid | Nicocap | Nicolar | Nicotinate | Wampocap | Enduracin | Induracin | Niacin Calcium Salt | Lithium Nicotinate | Nicotinate, Lithium | Niacin Aluminum Salt | Aluminum Salt, Niacin | Niacin Ammonium Salt | Niacin Lithium Salt | Niacin Cobalt (2+) Salt | Niacin Magnesium Salt | Niacin Manganese (2+) Salt
Chemical Information
Molecular Formula C6H4NO2-
CAS Registry Number 59-67-6
SMILES C1=CC(=CN=C1)C(=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Loss of consciousness17.02.04.004---
Lung disorder22.02.07.001---
Macular oedema06.04.06.005---
Migraine17.14.02.001; 24.03.05.003---
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005---
Muscular weakness15.05.06.001; 17.05.03.005--
Myalgia15.05.02.001--
Myopathy15.05.05.001---
Nausea07.01.07.001--
Necrosis08.03.03.001; 24.04.02.006---
Neoplasm skin16.03.02.003; 23.08.02.003---
Nervousness19.06.02.003---
Oedema08.01.07.006; 14.05.06.010---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Oesophagitis07.08.05.001--
Orthostatic hypotension17.05.01.020; 24.06.03.004---
Pain08.01.08.004--
Palpitations02.11.04.012--
Paraesthesia17.02.06.005; 23.03.03.094--
Peptic ulcer07.04.07.001---
Polyuria20.02.03.002---
Prostatic disorder21.04.01.001---
Pruritus23.03.12.001--
Rash23.03.13.001---
Rash maculo-papular23.03.13.004--
Rash pustular11.01.12.002; 23.03.10.003--
Rhabdomyolysis15.05.05.002--
Rhinitis11.01.13.004; 22.07.03.006--
Shock24.06.02.002---
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages